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 9 
We propose a model that characterizes and links the complexity and diversity of 10 
clinically observed Hepatitis C viral kinetics to sustained virologic response (SVR, the 11 
primary clinical endpoint of Hepatitis C treatment defined as an undetectable viral load 12 
at 24 weeks after treatment completion) in Chronic Hepatitis C (CHC) patients treated 13 
with peginterferon α-2a ± ribavirin. New attributes of our Hepatitis C viral kinetic 14 
model are- i) the implementation of a cure/viral eradication boundary, ii) employing all 15 
HCV RNA measurements including those below the lower limit of quantification, and 16 
iii) implementation of a population modeling approach. The model demonstrated 17 
excellent positive (99.3%) and negative (97.1%) predictive values for SVR and high 18 
sensitivity (96.6%) and specificity (99.4%). The proposed viral kinetic model provides a 19 
framework for mechanistic exploration of treatment outcome, and permits evaluation of 20 
alternative CHC treatment options to ultimately develop and test hypotheses for 21 
personalizing treatments in this disease. 22 
 23 





An estimated 170 million people or 2.1% of the world population are currently infected 24 
with hepatitis C virus (HCV), which is more than four times the number of people 25 
living with human immunodeficiency virus HIV (1). The current standard of care (SOC) 26 
for Chronic Hepatitis C (CHC) patients is the combination of pegylated interferon α 27 
with ribavirin (2,3). Successful HCV treatment outcome, i.e. sustained virologic 28 
response (SVR), is when a patient’s viral load is below the HCV RNA detection limit at 29 
a follow-up evaluation 24-weeks following treatment completion. SVR rates of up to 30 
66% have been obtained with the optimal regimen of peginterferon α-2a plus ribavirin 31 
in treatment-naïve patients in large, randomized, multicentre trials (4,5). Patients 32 
infected with the more difficult to treat HCV genotype 1 (G1), which represent about 33 
70% of CHC patients in the US (6), are less likely to achieve an SVR than genotype 34 
non-1 (Gn1) infected patients. Approximately 50% of HCV G1 infected patients 35 
achieved an SVR when treated with peginterferon α-2a plus ribavirin, whereas 36 
approximately 80% of HCV Gn1-infected patients achieved an SVR despite receiving a 37 
shorter treatment duration and a lower ribavirin dose (5). Thus, HCV patients represent 38 
a population with continued unmet medical need, having the potential to achieve a 39 
higher SVR rate through optimized treatment approaches. 40 
Modeling hepatitis C virus (HCV) dynamics during therapy has led to important 41 
insights into the life cycle of HCV elucidating the kinetic parameters governing viral 42 
infection and hepatocyte death, the antiviral effects of interferons, and how ribavirin 43 
impacts HCV treatment (7). Models of HCV kinetics have provided a means to compare 44 
different treatment regimens and outcomes in different patient populations (8). A model 45 
of HCV infection was originally proposed by Neumann et al. (9) who adapted a model 46 
of HIV infection (10,11). The Neumann model adequately describes typical short-term 47 





therapy outcome characterized by an initial rapid viral decline followed by a second 48 
slower decline until HCV RNA becomes undetectable (12,13). This model has therefore 49 
been frequently used to describe viral load profiles after short-term treatment (8,14,15). 50 
However, after current long-term SOC treatment, the virus is not eradicated in all CHC 51 
patients (5). In the patients who do not achieve SVR (i.e the virus is not eradicated), 52 
viral load either rebounds to pretreatment levels during therapy (breakthrough), or 53 
returns to pretreatment levels upon cessation of therapy (relapse) (13). These two 54 
phenomena, and crucially, an SVR cannot be described by the Neumann model (13), 55 
and are the primary reason why early viral response does not uniformly predict the 56 
clinical endpoint. Finally, and most importantly, previous analyses have used a naïve 57 
method of handling the HCV RNA measurements below the lower limit of 58 
quantification (LLOQ) by omission of all these measurements even though these values 59 
contain critical information regarding long-term treatment outcome.  60 
In this communication, we propose a novel approach of modelling the viral kinetics in 61 
Hepatitis C. Firstly, a non-linear mixed effects model was developed by maximum 62 
likelihood estimation (MLE) of the parameters using the extended stochastic 63 
approximation expectation-maximization (SAEM) algorithm as implemented in the 64 
MONOLIX software (16). Individual long-term HCV kinetic profiles of 2,100 CHC 65 
patients treated with peginterferon α-2a alone or in combination with ribavirin using a 66 
wide spectrum of dosing regimens were simultaneously described. Secondly, HCV 67 
RNA measurements below the LLOQ were included. The proposed model permits the 68 
distinction between SVR and LLOQ by including censored data residing between the 69 
HCV RNA LLOQ and the irrevocable lower boundary of zero. Thirdly, cure or 70 
complete virion eradication was determined from viral kinetics by implementation of a 71 





viral eradication boundary. At the time point at which treatment drives the system to 72 
less than one infected hepatocyte, the production of virions was set to zero. Modeling 73 
results characterizing differences between patients having an SVR and those failing 74 
treatment were explored in order to derive mechanistic hypotheses underpinning 75 
treatment failure or success. 76 
 77 
RESULTS 78 
Parameters of the model were estimated with good precision (Table 1). The typical 79 
value of the basic reproduction number R0 was estimated to be 7.2 with an inter-80 
individual variability (IIV) of 137% CV. The relatively large IIV likely reflects the large 81 
intrinsic biological difference in CHC disease. R0 represents relative drug-effect 82 
distance from the treatment intervention goal, which is to drive the reproduction number 83 
during treatment (RT) below 1 (Supplementary text note 2 online), in order to increase 84 
the likelihood of attaining SVR (i.e. cure, defined as I < 1 infected hepatocyte). 85 
Inspection of the individual parameter estimates in patients experiencing a breakthrough 86 
during therapy indeed showed that the administered drug therapy failed to decrease the 87 
reproduction number (RT) below 1 (17,18). The maximum hepatocyte proliferation rate 88 
(r) was 0.00562 day
-1
, and simulations based on this r revealed that the predicted liver 89 
regeneration matched well with the increase in original liver volume in 51 donors as 90 
measured 1 year after providing right-lobe liver grafts [Supplementary text note 3 91 
online (19)]. The typical value of the virion production rate p was 25.1 virions·day
-1
 and 92 
the free virion clearance rate c was estimated to be 4.53 day
-1
, corresponding to a free 93 
virion half-life of 3.7 hours. This half-life lies within the previously reported range of 94 
1.5-4.6 hours (12,13). Free virion clearance rate was found not to be influenced by HCV 95 





genotype. In contrast, the infected cell death rate (δ) appeared to be dependent on HCV 96 
genotype, and the typical value was estimated to be 0.139 day
-1
 in genotype-1 infected 97 
patients and 0.192 day
-1
 in patients infected with HCV Gn1 (Table 1). These estimates 98 
are in line with previously reported values of δ (20). The higher δ in HCV Gn1 infected 99 
patients may indicate an enhanced immunological response and is in line with the 100 
previous finding that a fast viral decay early in treatment correlates with SVR (20). Also 101 




 was found to be lower in HCV Gn1 patients as 102 
compared to patients infected with HCV G1, confirming the higher antiviral 103 
effectiveness of peginterferon α-2a in blocking virion production in Gn1 patients 104 








, which 105 
corresponds to rendering a fraction of 40-60% of the virions non-infectious for a 106 
standard ribavirin treatment of 1,000/1,200 mg per day (see equation 6). The anti-viral 107 
effect decay constant (K) was estimated to be 0.0238 day
-1
, which corresponds to a half-108 
life of approximately 29 days. As the terminal half-life after multiple dosing of 109 
peginterferon α-2a is approximately 160 h and that of ribavirin is approximately 12 110 
days (21), the anti-viral effect decay constant may describe both pharmacokinetic and 111 
pharmacodynamic processes. Finally, the variance of the residual error (σ
2
) was 112 
estimated to be 0.260. This residual error is relatively high but not uncommon for viral 113 
kinetic models as a σ
2
 of 0.38 was obtained previously in a similar analysis of HIV viral 114 
load data (22).  115 
 116 
Model evaluation and qualification 117 
The goodness of fit assessment revealed that the individual viral load profiles are well 118 
described by the model (Supplementary text note 4 online). Population based 119 





diagnostics were also used, but are not easily interpretable unless simulated reference 120 
graphs from the true model are used for comparison [Supplementary text note 4 online 121 
(23)]. A selection of 12 individual viral load profiles shows that the HCV viral kinetic 122 
model is able to not only describe the initial decreases in viral load over the first month, 123 
but also the typical phenomena observed after longer-term therapy (Figure 3). The 124 
model provided satisfactory positive (99.3%) and negative (97.1%) predictive values for 125 
SVR combined with a high sensitivity (96.6%) and specificity (99.4%) 126 
[Supplementary text note 5 online]. 127 
The predictive performance of the model was assessed by a model evaluation procedure 128 
using the design and data of a large clinical trial not included in the model building 129 
dataset (4). The model was successfully qualified for further simulations as the 130 
predicted range of SVR rate in HCV G1 and Gn1 infected patients receiving 48 weeks 131 
of treatment with peginterferon α-2a alone or in combination with ribavirin matched 132 
well with the observed SVR rate in this study (Figure 5). 133 
 134 
Discussion 135 
The multi-dimensional interactions between HCV virus, host and drug are highly non-136 
linear and equilibrium outcomes quickly become counter-intuitive (24). Here, we 137 
propose a population approach using MLE by the extended SAEM algorithm as 138 
implemented in the MONOLIX software (16), to simultaneously describe individual 139 
long-term HCV kinetic profiles of 2,100 CHC patients treated with peginterferon α-2a 140 
alone or in combination with ribavirin. The four ordinary differential equations (ODE’s) 141 
of the HCV viral kinetic model (equations 1-4) were implemented in MONOLIX. HCV 142 
viral kinetic models including ODE’s have been previously used for exploratory 143 





simulations (17,25), however not for simultaneously fitting the complexity and diversity 144 
of clinically observed HCV viral kinetics. 145 
The proposed model addresses the host-virus-drug interaction by advancing previously 146 
known and novel ideas from a population perspective, simultaneously analyzing a wide 147 
spectrum of treatment regimens (drug combinations, drug doses, schedule and treatment 148 
durations), incorporating left-censored data previously largely excluded from analysis, 149 
and implementing a viral eradication cure boundary to link viral kinetics to clinical 150 
outcome (i.e. SVR). The final viral kinetic model was qualified using internal and 151 
external datasets, including HCV G1 and Gn1 infected patients, and demonstrated 152 
positive and negative predictive values as well as sensitivity and specificity exceeding 153 
96%. 154 
In clinical practice, milestone target treatment strategies, i.e., rapid virologic response 155 
(RVR)- defined as attainment of undetectable HCV RNA level by week 4 of therapy 156 
(26,27), or early virologic response (EVR)- defined ≥ 2 log reduction or undetectable 157 
serum HCV RNA at week 12 of treatment, have been proposed to optimize SVR rates 158 
by modifying treatment duration. However, these early treatment response landmarks 159 
(regardless of time point) do not uniformly predict SVR because viral load either 160 
rebounds to pretreatment levels during therapy (breakthrough), or returns to 161 
pretreatment levels upon cessation of therapy (relapse). This observations leads to two 162 
conclusions, (i) the relationship between RVR/EVR and SVR is correlative but not 163 
prescriptive, and (ii) excluding HCV RNA measurements below the LLOQ (i.e., left-164 
censoring) likely biases SVR predictions. An extension of the SAEM algorithm as 165 
implemented in the MONOLIX software handles left-censored data in nonlinear mixed-166 
effects models with computational efficiency (22). Comparison with classical methods 167 





of handling missing data shows that the extended SAEM algorithm is less biased than 168 
excluding subjects with censored measurements, omission of all censored data points, 169 
and/or imputation to half the quantification limit for the first point below the LLOQ 170 
with omission of subsequent missing data (28). Furthermore, the extended SAEM 171 
algorithm has been demonstrated to be more efficient and/or less biased than 172 
linearization or Monte Carlo approximation of the expectation step applied to censored 173 
values (22). 174 
The implementation of the cure boundary in the viral kinetic model is physiologically 175 
based and consistent with the primary goal of HCV therapy, which is to completely 176 
eradicate the virus. The final viral kinetic model was implemented as a two state system. 177 
The off state (null virion production) was triggered when there was less than one 178 
infected hepatocyte in the total plasma and extracellular fluid volume of distribution 179 
thereby resulting in cure/SVR. The on state (constitutive virion production), 180 
inadvertedly returns the patient to full blown disease when even a minute fraction of one 181 
infected hepatocyte remains.  182 
A comparison of the individual parameter estimates between patients with and without 183 




are generally lower in SVR patients (Figure 4). A 184 
relatively low R0 prior to treatment and a relatively high inhibition of the virion 185 
production increase the likelihood of RT < 1 during treatment and will thus increase the 186 
likelihood of SVR.  187 
Inspection of the individual parameter estimates in patients experiencing a breakthrough 188 
during therapy indeed showed that the administered drug therapy failed to decrease the 189 
RT below 1 (17,18). According to our modeling assumptions, a treatment with either 190 
higher doses or a combination treatment with new drugs may be an option in these 191 





patients in order to drive RT below 1. The conditional explanation in patients relapsing 192 
after the end of treatment may be twofold: i) on the one hand, relapsing patients may 193 
have had a RT < 1 during treatment, but were not treated long enough to cross the cure 194 
boundary of I < 1 cell, so that the viral load quickly returned back to baseline at the end 195 
of therapy, or ii) drug therapy may have failed to decrease the RT below 1 (inadequate 196 
efficacy). Extended treatment duration at the same drug combination, dose and schedule 197 
in relapsing patients may therefore be an option in the former situation but not in the 198 
latter. Based on these hypotheses, individual treatments may be optimized when the 199 
individual R0 and inhibition of the virion production are pre-determined or determined 200 
early at treatment onset. The interplay between treatment duration, dose and schedule, 201 
and/or sensitivity of hitting the cure boundary after high dose induction is yet to be fully 202 
elucidated. 203 
In our model-based analysis, the free virion clearance rate (c) did not appear to be a 204 
prognostic factor for SVR (Figure 4), whereas the death rate of infected cells (δ) was 205 
found to be generally higher in SVR patients indicating these patients may have an 206 
enhanced immunological response and thus a higher likelihood of viral eradication. 207 
Our proposed viral kinetic model is a simplification of the complex interaction between 208 
host, infected hepatocytes, virus, and mechanisms of drug action and required fixing of 209 
several liver physiology parameters to biologically justifiable values. Furthermore, the 210 
combination of peginterferon α-2a and ribavirin is assumed to inhibit in a multiplicative 211 
way the virion production (p) according to Emax dose-response relationships. While 212 
some confidence in the predictive performance of the model is derived from the 213 
qualification exercise described above, complete understanding of the implications of 214 
these assumptions is not fully understood and should be further explored, particularly in 215 





the case where the model would be used to explore the efficacy of new drugs in 216 
combination with SOC. Another limitation of our current model is the fact that dose was 217 
used as the pertubation to the system. Since HCV SOC pharmacotherapy has been 218 
established through empirical study over a decade, investigation of schedule 219 
dependence was not considered as primary to our objectives. This implies that a 220 
pharmacokinetic model component will have to be added to the current model for the 221 
evaluation of schedule dependence and/or adherence, especially for drugs with shorter 222 
pharmacokinetic half-lives that are being developed. 223 
In summary, our population HCV viral kinetic model was able to adequately describe 224 
all individual long-term viral load profiles of 2,100 CHC patients receiving chronic 225 
treatment of peginterferon α-2a alone or in combination with ribavirin. The model 226 
provides new insights and explanations for typical phenomena observed in the clinic 227 
such as breakthrough during therapy, relapse after stopping therapy and cure (or SVR). 228 
Simulations based on our model may help to better understand current treatment success 229 
and failure, and can also be used to predict and evaluate the efficacy of alternative 230 
treatment options (e.g. alternative doses, durations and, with additional assumptions- 231 
new drug combinations) in the overall CHC patient population. This will be described in 232 
a follow-up communication. The proposed viral kinetic model provides a framework for 233 
developing and testing hypotheses for evaluating new antiviral agents and personalizing 234 




Patients and Data 239 





Data from one phase-II study and four phase-III studies of peginterferon α-2a (40KD) 240 
(Pegasys
®
) alone or in combination with ribavirin (Copegus
®
) were pooled. All patients 241 
were required to have histologically and serologically proven CHC. The complete 242 
inclusion and exclusion criteria, study design, and primary results have been published 243 
elsewhere (5, 29-32). A total of 2,100 CHC patients were included in the final database. 244 
Serum HCV RNA (COBAS AMPLICOR

 HCV Test, version 2.0) was measured at 245 
specific time points during treatment and during the 24-week untreated follow-up 246 
period. All available 21,284 HCV RNA measurements, of which 59% were below the 247 
LLOQ, were modeled by accounting for the left-censoring in the analysis. The LLOQ of 248 
the two different assays used were 50 IU/mL and 600 IU/mL (33). 249 
 250 
HCV viral kinetic model 251 
The viral kinetic model (equations 1-4) extends the original Neumann (9) model, to 252 
include important contributions by Dahari et al. (density dependent proliferation of 253 
hepatocytes [r], 17) and Pomfret et al. (hepatocyte intrinsic production, 19). Treatment 254 
effect of peginterferon α-2a [ε] and the effect of ribavirin rendering a fraction of newly 255 
produced virions non-infectious [ρ] (7) was implemented on the virion production rate 256 
(p). The model structure of the viral kinetic model (Figure 1) is described by the 257 
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⋅−⋅⋅−⋅= )1( ερ  (4) 262 
where, infectious HCV virions (VI) infect target cells (uninfected hepatocytes) [T], 263 
creating productively infected cells (I) at a rate β·VI·T. Uninfected hepatocytes are 264 
produced at rate s and die at rate d. Infected hepatocytes die at rate δ. Similar to Dixit et 265 
al. (7), it is assumed that infectious (VI) and non-infectious (VNI) virions are produced 266 
from infected hepatocytes at rate p and cleared at rate c. The measured viral load (V) is 267 
expressed in IU/mL, representing the sum of infectious and non-infectious virions V = 268 
VI + VNI. The model was further extended with Emax dose-response models describing 269 


















 (6) 272 
where PEGDose  is the weekly subcutaneous dose of peginterferon α-2a and PEGED50 is 273 
the estimated weekly dose of peginterferon α-2a resulting in a 50% inhibition of the 274 





is the estimated daily dose in mg/kg rendering 50% of the virions non-276 
infectious. RBVDose  and RBVED50  were expressed as mg/kg as ribavirin is dosed by body 277 
weight and ribavirin in mg/kg has been previously found to be a prognostic factor for 278 
SVR (34). 279 
The implementation of a cure/viral eradication boundary represents a milestone 280 
contribution in enabling linking the complexity and diversity of clinically observed 281 
Hepatitis C viral kinetics to SVR. The cure boundary was based on the assumption that 282 





virion production (p) should cease when all infected cells are cleared, i.e., when there is 283 
less that 1 infected cell in the total plasma and extracellular fluid volume of 284 
approximately 13.5·10
3
 mL. At the time point at which treatment anti-viral effect drove 285 
the system to less than one infected hepatocyte, the virion production p was set to zero 286 
(off state), resulting in a model cure/SVR [Supplementary text note 1 online (35)]. 287 
Exploratory simulations without this additional model component of cure predicted 288 
rapid viral load return to baseline in all CHC patients when treatment was stopped 289 
[Supplementary text note 1 online (35)], while in reality the virus is eradicated after 290 
the current standard treatment of care in the majority of Gn1 infected patients and 291 
approximately half of the HCV G1 patients and approximately (5).  292 
A fundamental parameter of the viral kinetic model is the estimated basic reproduction 293 
number (R0) [Supplementary text note 2 online (18)]. Previously, it was shown that the 294 
reproduction number in the presence of an inhibitor (RT) is (36): 295 
)1(0 TT RR ε−⋅=  (8) 296 
where Tε  is the total treatment-induced inhibition of the virion production. As infection 297 
in the presence of an inhibitor has been shown to be cleared when RT < 1 (36), Tε  298 
combined with R0 are thus important predictors for a successful drug therapy. For this 299 
reason, our model was parameterized in terms of R0, by using the following equation for 300 










 (9) 302 
Finally, drug-effect after stopping treatment was described by an exponential decay 303 
function ( K te− ⋅ , Figure 2), where K is the estimated antiviral-effect decay constant and t 304 
the time from the end of treatment. Without the inclusion of this exponential decay 305 





function, the viral load in relapsing patients after stopping therapy appeared to return 306 
too rapidly to pre-treatment values 307 
 308 
Model assumptions 309 
Currently available data did not allow the estimation of all parameters of the declared 310 
viral kinetic model due to issues of mathematical identifiability. For this reason, a 311 
number of system/physiological parameters were fixed to biologically justifiable values. 312 
The maximum number of hepatocytes present in an individual liver was assumed to be 313 
2.50·10
11
 hepatocytes (37). As HCV RNA is distributed in plasma and extracellular 314 
fluids with a volume of approximately 13.5·10
3
 mL (38), the maximum number of 315 




 (12). Assuming a hepatocyte 316 
turnover in a healthy liver of 300 days (39), the death rate of target cells (d) was set to 317 
1/300 day
-1
, and therefrom (Tmax·d) the production of new hepatocytes in the absence of 318 






 (12). Estimated 319 
proliferation rates were set to be equal across infected and uninfected hepatocytes due to 320 
a lack of direct information to the contrary. 321 
Non-linear mixed effects models comprise of a combination of fixed and random 322 
effects. Individual parameters (PARi) in such a model are assumed to be log-normally 323 
distributed and can be described by: 324 
i
iPAR e
ηθ= ⋅  (7) 325 
where, subscript i denotes individual, the fixed effects parameter θ  represents the 326 
median (typical) value of the parameter in the population, and iη  is the random effect 327 
accounting for the individual difference from the typical value. The iη  values are 328 
assumed to be normally distributed in the population with a mean of zero and an 329 





estimated variance of ω2 . Individual parameter estimates are used to predict the viral 330 
load in an individual i at a certain point in time j (Vpred,ij). The measured viral load data 331 
(Vobs,ij) were log10-transformed for the analysis in order to be able to handle the wide 332 
range of viral load observations, and an additive residual error model was used for the 333 
log10-transfomed viral load data: 334 
obs ,ij pred ,ij ijlog V log V ε= +10 10  (8) 335 
The εij values are assumed to be normally distributed with a mean of zero and an 336 
estimated variance σ
2
. The ω2  quantifies the inter-individual variability (IIV) and the σ2 337 
quantifies the residual variability. 338 
Estimated fixed effects parameters were R0, p, c, δ, liver proliferation rate r 339 








 and K. IIV was incorporated 340 




.  341 
 342 
Parameter estimation 343 
Population parameters of our HCV viral kinetic model were estimated using MLE by 344 
the SAEM algorithm for hierarchical nonlinear mixed effects model analysis (40,41). 345 
Individual parameters were obtained by computing for each individual patient the so-346 
called Maximum A Posteriori (MAP) esimate, which maximizes the conditional 347 
distribution of the individual parameters using the MLE of the population parameters 348 
computed previously with the SAEM algorithm (40). SAEM is a powerful algorithm for 349 
MLE in complex models, including dynamic models defined by a system of ODE’s. 350 
Furthermore, the left-censored data are properly handled by the extended SAEM 351 
algorithm for MLE as described by Samson et al. (22). The extended SAEM algorithm 352 





for MLE is implemented in the MONOLIX software, available on the author’s website 353 
(16). We used version 2.4 of MONOLIX. 354 
 355 
Model evaluation and qualification 356 
Goodness of fit was assessed by the method of simulating from the final model and re-357 
fitting (23). Since by definition, the proposed model does not characterize SVR directly, 358 
but SVR is derived from crossing the model cure boundary, the predictive performance 359 
of the model in correctly classifying patients into SVR or non-SVR, which is considered 360 
one of the core utilities of the model, could be assessed by calculating the sensitivity 361 
and specificity (42,43) without confounding bias. The predictive performance of the 362 
model was assessed by a model evaluation procedure using the design and data of a 363 
large clinical trial not included in the model building dataset. In this trial, 180 µg 364 
peginterferon α-2a was administered once weekly for 48 weeks, alone or in 365 
combination with daily 1,000 or 1,200 mg ribavirin (4). Dropout rates in the simulated 366 
cohort were matched to historical data by random assignment and defining dropouts as 367 
non-SVR. The uncertainty of the observed SVR rates was quantified by 400 bootstrap 368 
samples and compared to observed SVR rates in the trial. 369 
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Figure 1. Representation of the extended HCV viral kinetic model. Infectious HCV virions 
(VI) infect target cells (T), creating productively infected hepatocytes (I). Uninfected 
hepatocytes (T) are produced at rate s and die at rate d. Infected hepatocytes die at rate δ. A 
density dependent proliferation of hepatocytes (r) is assumed. Infectious (VI) and non-
infectious (VNI) virions are produced at rate p and cleared at rate c. Peginterferon α-2a dose-
dependently inhibits the production of new virions (ε), and ribavirin dose-dependently renders 
a fraction of newly produced virions non-infectious (ρ). SVR, defined as an undetectable viral 
load at 24 weeks after treatment completion, is the primary clinical endpoint desired to be 
predicted in the treatment of Hepatitis C. 
Page 67 of 110
Official journal of the American Society for Clinical Pharmacology and Therapeutics                                 www.nature.com/cpt









Figure 2. The viral kinetic model characterizes the complexity and diversity of clinically 
observed HCV viral kinetics in Hepatitis C virus patients treated with peginterferon α-2a alone 
or in combination with ribavirin, and links the kinetics to clinical outcome. This is achieved by 
the implementation of a viral eradication cure boundary and incorporation of left-censored 
data, previously largely excluded from analysis, from simultaneous analysis of a wide 
spectrum of peginterferon α-2a ± ribavirin treatment regimens from 2,100 patients. RVR and 
EVR are rapid virologic response and early virologic response, respectively. 
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Figure 3. Observed and model-predicted long-term viral load profiles in 12 representative 
CHC patients. Solid lines are the fits of the model to the individual viral load data which are 
either detectable (closed circles) or below the LLOQ of 50 IU/mL (closed triangles). Dotted 
horizontal lines show the LLOQ of the assay. Dotted vertical lines indicate the end of 
treatment. Our HCV viral kinetic model is able to describe all the typical phenomena observed 
after long-term therapy such as null response (no change in viral load), partial virologic 
response (initial decrease followed by increase during treatment), breakthrough during therapy 
(non-detectable viral load followed by increase during treatment), relapse after therapy (non-
detectable viral load at the end of therapy followed by an increase during the treatment-free 
follow-up period), and SVR (non-detectable viral load at 24 weeks after end of therapy). 
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Figure 4. Boxplots of the individual HCV viral kinetic model parameters as split by patient 
outcome (i.e. SVR (n = 974) versus non-SVR (n = 1,126) patients). The basic reproduction 
number (R0) is generally higher and more variable in patients without an SVR (A). The free 
virion clearance rate (c) is not different between patients with and without an SVR (B). The 
infected cell death rate (δ) is generally higher in patients with an SVR (C), and the 
effectiveness of peginterferon α-2a in inhibiting the production of new virions is generally 
higher in patients with an SVR (D). 
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Figure 5. Observed (black vertical lines) and model predicted SVR rates (transparent 
histogram) of the phase-III study by Fried et al. (4), investigating 180 µg peginterferon α-2a 
once weekly for 48 weeks given alone or in combination with daily 1,000 or 1,200 mg 
ribavirin. Dropouts have been taken into account in the predictions by randomly assigning 
patients as dropout and defining them as non-SVR. The uncertainty of the observed SVR rates 
was quantified by 400 bootstrap samples (grey histograms). The observed SVR rate in 297 
HCV G1 patients receiving combination therapy falls within the range of model predicted 
SVR rates (A). The observed SVR rate in 154 HCV Gn1 patients receiving combination 
therapy also falls within the range of model predicted SVR rates (B). The observed SVR rate 
in 143 HCV G1 patients receiving monotherapy of peginterferon α-2a falls within the range of 
model predicted SVR rates (C). Finally, also the observed SVR rate in 77 HCV Gn1 patients 
receiving monotherapy of peginterferon α-2a falls within the range of model predicted SVR 
rates (D). 
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Table 1. Population parameters of the HCV viral kinetic model fitted to the individual long-term viral load profiles of 2,100 CHC patients receiving 
chronic treatment of peginterferon α-2a alone or in combination with ribavirin*. The upper part of the table represents the fixed parameters according 
to our assumptions, the middle part are system-specific parameters and the lower part are the drug-specific parameters. The SE reflects the precision of 
the estimated parameters and IIV represents the inter-individual variability (Supplementary text note 5 online). 
 
Parameter Description Unit Typical value SE (%CV)
***
 IIV (%CV) 











   
d Hepatocyte death rate constant day
-1
 0.003   
r Hepatocyte proliferation rate constant day
-1
 0.00562 22  
R0
**** Basic reproductive number  7.15 9 137 




 25.1 15  
c Virion elimination rate constant day
-1
 4.53 15 120 
δHCV non-1 Infected cell death rate constant (HCVGn1) day
-1
 0.192 16 58
*
 
δHCV-1 Infected cell death rate constant (HCV G1) day
-1
 0.139 3 58
*
 
PEG  HCV non-1
ED
50












 14.4 18  
K Anti-viral effect decay constant day
-1
 0.0238 13  
σ
2 Residual error  0.260 1  
 
 * 
47% received monotherapy of peginterferon α-2a at a weekly subcutaneous dose of 45 µg (20 patients), 90 µg (114 patients), 135 µg (210 patients), 180 µg (596 patients) or 
270 µg (38 patients). The CHC patients receiving combination therapy were administered a subcutaneous dose of 180 µg/week peginterferon α-2a and a daily dose of 800 mg 
or 1,000/1,200 mg ribavirin. Almost all patients (93%) received 24 weeks of treatment or more, and 61% of CHC patients received 48 weeks of treatment or more. 
 ** 
Assumed to be similar between HCV genotype-1 and non-1 infected patients. 
 *** 
As Tmax, s and d were fixed, no SE is provided. 
 **** R0 is defined as the number of newly infected cells that arise from one infected cell when almost all cells are uninfected and has therefore no units. 
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Supplementary text note 1: additional model component for HCV virion 
eradication 
Exploratory simulations were undertaken based on the HCV viral kinetic model as 
described by equations 1-6 of the manuscript. An evaluation of the simulated viral load 
profiles of the CHC patient population revealed that the viral load in all patients rapidly 
returned back to baseline within approximately 4 to 8 weeks after stopping the 48-week 
treatment (Figure S1). This implies that an SVR cannot be described without adding a 
model component for HCV virion eradication. A subsequent simulation based on the 
same model where only one infected cell (I) remained at the end of treatment showed 
again a rapid return to baseline within approximately 4 weeks (Figure S2). As the 
virion production p should cease when all infected hepatocytes are cleared, parameter p
was set to zero (off state) during the model fitting procedure when the number of 




Supplementary text note 2: basic reproduction number (R0) 
The basic reproduction number of an infection is defined as the number of newly 
infected hepatocytes that arise from one infected cell when almost all cells are infected, 
i.e. prior to treatment initiation (S1). When R0 < 1, the infection will be spontaneously 
cleared in the long run. But if R0 > 1, the infection will be able to expand. When R0 = 1, 
the infection will not be cleared or expand but remain at some quasi-disease 
equilibrium. Using a simple PK-PD model for proliferative systems, it can be shown 
that the reproduction number in the presence of an inhibitor of the virion production 
(RT) is (S2): 
)1(0 TT RR ε−⋅= (1) 






ε  is the total treatment-induced inhibition of the virion production. The 
infection in the presence of an inhibitor will die out in case RT < 1 (S2). R0 thus carries 
information on the status of infection, whereas RT carries information about treatment 
effect and the likelihood of cure.
Simulations based on our HCV viral kinetic model confirmed the previous findings 
based on the simple PK-PD model for proliferative systems (Figure S3). The total drug 
effectiveness 
T
ε  combined with R0 are thus important predictors for successful drug 
therapy. For this reason, our model was parameterized in terms of R0, by using the 




















, whereas R0, c, p and δ are estimated so that the de novo
infection rate constant β can be calculated. 
Supplementary text note 3: liver proliferation rate (r) 
The liver is a unique organ as it self-heals by regeneration as opposed to repair. The 
exact cellular and molecular mechanisms of liver regeneration are still not yet fully 
understood (S4,S5). The Neumann HCV viral kinetic model was extended with a 
density-dependent liver proliferation term to describe the liver regeneration (S6). For 




s r T d T
dt T
 
= + ⋅ ⋅ − − ⋅ 
 
1 (3) 
T represents the number of hepatocytes in cells·mL
-1
. The maximum number of 









The death rate of hepatocytes (d) is assumed to be 1/300 day
-1
, and the production of 






 from steady-state assumptions. 
Simulations of the liver regeneration based on the above mentioned equation and the 
model estimated a maximum liver proliferation rate (r) of 0.006 day
-1
, and also revealed 
a rapid initial liver regrowth (Figure S4). For a donor remnant liver volume of 50%, the 
total liver volume was predicted to be approximately 89% after 360 days. This predicted 
total liver volume matched well with the increase in original liver volume as measured 
over a 1-year time period in 51 donors who provided right-lobe liver grafts (S7). 
Supplementary text note 4: goodness of fit assessment 
As anticipated, a diagnostic plot of the observed viral load values (DV) versus the 
population predictions (PRED) [Figure S5] is neither intuitive nor very informative. 
Because of the wide diversity of the various viral load profiles (Figure 3 of 
manuscript), the population based diagnostic plots have limited meaning for the 
assessment of the goodness of fit. In principle, the population prediction would be the 
same for a null-responder, a breakthrough patient, a patient having a relapse and a SVR 
patient. This implies that conditional estimates of the model parameters should be taken 
into account for model diagnostics based on population predictions to make sense. A 
plot of the population weighted residuals (WRES) versus PRED [Figure S6] shows a 
certain pattern which can be well explained by comparing the time course of the 
population predicted viral load with the individual viral load values. In order to assess 
the expected pattern of the DV versus PRED and WRES versus PRED plots of our 
model, mirror plots were created in which “observations” were simulated three times 
from the final model and these “observations” were subsequently re-fitted to create the 
PRED and WRES plots based on the parameters used in the simulation (Figures S5-




S6). The patterns of the PRED- and WRES-based diagnostics for the observed and 
simulated data were similar, implying that the observed pattern of these two population-
based diagnostic plots matched with the expected pattern for our model (S8). 
As population based diagnostics were not very infomative, goodness of fit was assessed 
based on diagnostic plots for the individual predictions (IPRED) [Figure S7], individual 
weighted residuals (IWRES) [Figure S8] and the absolute values of the individual 
weighted residuals (|IWRES|) [Figure S9]. The ε–shrinkage was calculated to be 9%, 
implying that individual predictions can be used as a reliable diagnostic (S8). Mirror 
plots were also created for IPRED, IWRES and |IWRES| (Figures S7-S9). The patterns 
of the goodness of fit plots for IPRED, IWRES and |IWRES| for the observed and 
simulated data were similar, implying that no model misspecification was evident from 
the diagnostic (S8), and thus indicating that the individual viral load profiles are well 
described by the model. In addition, the goodness of fit plot of |IWRES| versus IPRED 
indicates that the residual error model was appropriate. 
The η–shrinkage was calculated to be 39% for the basic reproduction number (R0), 17% 




. As anticipated, the relatively high shrinkage values are driven by the typical 
viral load profiles of the different patient categories (i.e. null-responders, breakthrough 
patients, relapsing patients and patients having an SVR). For instance, the shrinkage of 
δ, describing the second phase of the viral load decay, was only 4% in breakthrough 
patients and 17% in patients having a relapse. These two patient categories generally 
have a relatively slow decay of the viral load so that the individual values of δ can be 
well estimated. SVR-patient viral load decline was generally characterized by a fast 
decay so that the second phase is not always visible, while null or partial responding 




patients, had a relatively flat profile, and the δ estimate was more shrunken towards the 
population mean. 
Supplementary text note 5: performance of model-based SVR classification 
Statistical measures of the performance of the SVR classification by the HCV viral 
kinetic model were obtained by comparing the SVR classification (SVR or non-SVR) 
based on the model to the observed SVR classification in each individual patient present 
in the database of 2,100 CHC patients. Since by definition, the proposed model does not 
characterize SVR directly, but SVR is derived from crossing the model cure boundary, 
the performance of the model related to correctly classifying patients could be assessed 
by calculating the sensitivity and specificity based on individual predictions of HCV 
RNA including those obtained post-treatment (9,10) without confounding bias. A total 
of 941 patients were found to be True Positive (observed SVR and model-predicted 
SVR), and 1,119 CHC patients were found to be True Negative (observed non-SVR and 
model-predicted non-SVR) [Table S1]. A total of 33 patients were found to be False 
Negative (observed SVR but model-predicted non-SVR), and 7 patients were found to 
be False Positive (observed non-SVR but model-predicted SVR). Based on these 
numbers, the sensitivity and specificity was calculated to be 96.6% and 99.4%, 
respectively. Although the difference in the number of correctly and incorrectly 
classified individuals is quite convincing, it should be noted that the sensitivity and 
specificity are positively biased as the rows and columns of Table S1 are not fully 
independent. The positive predictive value (PPV) and negative predictive value (NPV) 
was calculated to be 99.3% and 97.1%, respectively. In calculating these two statistics, 
it is assumed that the prevalence in the population at large is similar. 


































































































































Figure S1. Simulated long-term viral load profiles in 12 CHC patients receiving a 48-





, c = 3 day
-1
, δ = 0.2 day
-1
, r = 0.005 day
-1
 and an inhibition of the virion 
production of 80%. IIV was assumed to be 40 %CV for R0 and 20% CV for all other 
parameters. Simulated individual viral load data are either detectable (closed circles) or 
below the LLOQ of 50 IU/mL (closed triangles). Dotted horizontal lines show the 
LLOQ of the assay. Vertical lines indicate the end of treatment at 48 weeks. 























































Figure S2. Simulated HCV viral load (black line) and simulated number of infected 
hepatocytes (grey dashed line) with only one infected cell remained at the end of 




, c = 3 
day
-1
, δ = 0.2 day
-1
 and liver proliferation rate r = 0.005 day
-1
. The dotted horizontal 
lines show the LLOQ of the assay of 50 IU/mL. 

































RT = 0.95RT = 0.9
Figure S3. Simulated HCV viral load profiles during a 192-week antiviral therapy 
resulting in a continuous 50% inhibition of the virion production (ε = 0.5). Simulations 




, c = 3 day
-1
, δ = 0.16 day
-1
 and r = 0.01 
day
-1
. The dotted horizontal line shows the LLOQ of the assay of 50 IU/mL. The basic 
reproductive number (R0) was assumed to be 2.4, 2.2, 2.1, 2.0, 1.9 and 1.8, respectively 
resulting in a basic reproduction number in the presence of a 50% inhibition of the 
virion production (RT) of 1.2, 1.1, 1.05, 1.0, 0.95 and 0.9 (see equation S1). Simulations 
confirmed that when RT < 1, the infection will be cleared in the long run. But if RT > 1, 
the infection will expand. When RT = 1, the infection will not be cleared or expand but 
remain at some quasi-disease equilibrium. 































Figure S4. Simulated liver regeneration after a donor remnant liver volume of 50%, 
60%, 70%, 80% and 90% of the original total liver volume. Simulations were performed 
with the model estimated maximum liver proliferation rate (r) of 0.006 day
-1
.




Figure S5. Mirror plot of the observed versus population predictions (PRED) for the 
HCV viral kinetic model fitted to the actual data (upper left panel) and when all 
“observations” are simulated three times with the same model as is used to calculate the 
individual predictions (upper right panel and lower panels). The predicted values are 
based on the estimated parameter values. The solid black line is the line of identity 
which should go through the middle of the data. Simulations were undertaken with an 
LLOQ of 50 IU/mL explaining the presence of more lower “observed” values in the 
simulations. 




Figure S6. Mirror plot of the weighted residuals (WRES) versus population predictions 
(PRED) for the HCV viral kinetic model fitted to the actual data (upper left panel) and 
when all “observations” are simulated three times with the same model as is used to 
calculate the WRES (upper right panel and lower panels). The solid black line is the 
zero line.  




Figure S7. Mirror plot of the observed versus individual predictions (IPRED) for the 
HCV viral kinetic model fitted to the actual data (upper left panel) and when all 
“observations” are simulated three times with the same model as is used to calculate the 
individual predictions (upper right panel and lower panels). The predicted values are 
based on the estimated parameter values. The grey line represents a smooth through the 
data. The solid black line is the line of identity which should go through the middle of 
the data. Simulations were undertaken with an LLOQ of 50 IU/mL explaining the 
presence of more lower “observed” and IPRED values in the simulations. 




Figure S8. Mirror plot of the individual weighted residuals (IWRES) versus individual 
predictions (IPRED) for the HCV viral kinetic model fitted to the actual data (upper left 
panel) and when all “observations” are simulated three times with the same model as is 
used to calculate the IWRES (upper right panel and lower panels). The grey line 
represents a smooth through the data. The solid black line is the zero line around which 
the values of IWRES should be randomly and densely scattered. Simulations were 
undertaken with an LLOQ of 50 IU/mL explaining the presence of more lower IPRED 
values in the simulations. Some higher IWRES values are present for small IPRED 
values based on the actual data. However, these data points present only a minor 
fraction of the overall data. 




Figure S9. Mirror plot of the absolute values of the individual weighted residuals 
(|IWRES|) versus individual predictions for the HCV viral kinetic model fitted to the 
actual data (upper left panel) and when all “observations” are simulated three times with 
the same model as is used to calculate the |IWRES| (upper right panel and lower 
panels). Simulations were undertaken with an LLOQ of 50 IU/mL explaining the 
presence of more lower IPRED values in the simulations. Some higher |IWRES| values 
are present for small IPRED values based on the actual data. However, these data points 
present only a minor fraction of the overall data. 




Table S1. Calculation of the sensitivity, specificity, positive predictive value (PPV) and 
negative predictive value (NPV) for the model-based classification of CHC patients into 
SVR or non-SVR. 
  Observed SVR 
  SVR = 1 SVR = 0 
Total 








 = 99.3% 


















 = 99.4% 
2,100
1
Sensitivity is calculated as 941 divided by 974 and expressed as %. 
2
Specificity is calculated as 1,119 divided by 1,126 and expressed as %. 
3
Positive predicted value (PPV) is calculated as 941 divided by 948 and expressed as %. 
4
Negative predictive value (NPV) is calculated as 1,119 divided by 1,152 and expressed as %. 
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